NorthRock Partners LLC Acquires New Holdings in Exact Sciences Co. (NASDAQ:EXAS)

NorthRock Partners LLC bought a new position in Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,040 shares of the medical research company’s stock, valued at approximately $207,000.

Other hedge funds also recently modified their holdings of the company. Chicago Partners Investment Group LLC boosted its holdings in Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after purchasing an additional 158 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Exact Sciences by 1.7% during the 1st quarter. Daiwa Securities Group Inc. now owns 11,947 shares of the medical research company’s stock worth $825,000 after acquiring an additional 200 shares in the last quarter. Amalgamated Bank increased its holdings in shares of Exact Sciences by 2.7% during the 2nd quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 284 shares during the last quarter. Midwest Professional Planners LTD. raised its stake in shares of Exact Sciences by 12.3% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,088 shares of the medical research company’s stock valued at $213,000 after acquiring an additional 339 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in Exact Sciences by 92.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after purchasing an additional 340 shares during the last quarter. Institutional investors and hedge funds own 88.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Citigroup dropped their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday. Piper Sandler boosted their target price on shares of Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, September 12th. Robert W. Baird lowered their price target on Exact Sciences from $70.00 to $67.00 and set an “outperform” rating on the stock in a research report on Wednesday. Stifel Nicolaus cut their price objective on Exact Sciences from $82.00 to $67.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Wells Fargo & Company assumed coverage on Exact Sciences in a research note on Tuesday, August 27th. They set an “overweight” rating and a $75.00 target price for the company. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $75.06.

Exact Sciences Trading Down 23.5 %

Shares of EXAS stock opened at $54.72 on Thursday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. The firm has a fifty day moving average of $67.27 and a 200-day moving average of $56.67. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of -57.00 and a beta of 1.27.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The business had revenue of $708.66 million for the quarter, compared to the consensus estimate of $716.80 million. The business’s revenue for the quarter was up 12.8% compared to the same quarter last year. On average, equities research analysts forecast that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.

Insider Activity at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at $893,060. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.36% of the stock is owned by insiders.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.